A new study reveals that adults diagnosed with type 1 diabetes face a heightened risk of cardiovascular disease and death, with no better prognosis than those diagnosed in childhood.
The Pfizer and BioNTech vaccine appears to be significantly less efficient against the South African mutation, but can still stop hosts from experiencing severe COVID and dying from the virus.
New data from the REACT study finds that the number of COVID cases in hospitals is higher than it was in April 2020, but that infection rates are substantially decreasing across the country.
A research team at MIT have created a machine-learning strategy to identify existing drugs that could be repurposed to fight COVID-19 in elderly patients.
The World Health Organisation have suggested that the Oxford and AstraZeneca vaccine can be safely used for all age groups, including those aged 65 and over.
The new results led to the South African Government suspending use of AstraZeneca in their vaccination programme, as it is no longer able to stop the mutation - but could still prevent hospitalisation and fatality.
Phase Three data from the UK trial shows that Novavax still works powerfully against the UK mutation, with a less intense impact on the South African mutation at 60%.
EU leaders are investigating why AstraZeneca are not following through with the pre-agreed number of vaccines for the Member States - taking a 60% cut to the expected amount.
The São Paulo Government and Butantan Institute revealed that the Sinovac COVID-19 vaccine is 15.6% less effective than officials previously suggested.
The projects will happen in 14 Member States and the United Kingdom, with 36 million in funding to get COVID-19 plasma to patients - boosting their immune response to the virus.
The approval of the Moderna COVID vaccine in the UK comes 2 days after European medical regulators, but not a moment too soon - the death toll continues to climb, standing at 78,508 currently.
